Cover and table of contents

151K characters. Original on sec.gov · Markdown

Cover and table of contents

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 1-5975

HUMANA INC.

(Exact name of registrant as specified in its charter)
Delaware61-0647538
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)

500 West Main Street

Louisville, Kentucky 40202

(Address of principal executive offices, including zip code)

(502) 580-1000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered
Common stock, $0.16 2/3 par valueHUMNew York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

Class of Common StockOutstanding at September 30, 2023
$0.16 2/3 par value123,110,720 shares

Table of Contents

Humana Inc.

FORM 10-Q

SEPTEMBER 30, 2023

INDEX

Page
Part I: Financial Information
Item 1.Financial Statements
Condensed Consolidated Balance Sheets (Unaudited) at September 30, 2023 and December 31, 20223
Condensed Consolidated Statements of Income (Unaudited) for the three and nine months ended September 30, 2023 and 20224
Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three and nine months ended September 30, 2023 and 20225
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) for the three and nine months ended September 30, 2023 and 20226
Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2023 and 20228
Notes to Condensed Consolidated Financial Statements (Unaudited)10
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations36
Item 3.Quantitative and Qualitative Disclosures about Market Risk54
Item 4.Controls and Procedures54
Part II: Other Information
Item 1.Legal Proceedings55
Item 1A.Risk Factors55
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds55
Item 3.Defaults Upon Senior Securities55
Item 4.Mine Safety Disclosures55
Item 5.Other Information56
Item 6.Exhibits57
Signatures58
Certifications

Humana Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

September 30, 2023December 31, 2022
(in millions, except share amounts)
ASSETS
Current assets:
Cash and cash equivalents$15,148$5,061
Investment securities15,14513,881
Receivables, net of allowances of $73 in 2023 and $70 in 20221,8241,674
Other current assets6,1365,567
Total current assets38,25326,183
Property and equipment, net3,3423,221
Long-term investment securities370380
Equity method investments762749
Goodwill9,5409,142
Other long-term assets3,6383,380
Total assets$55,905$43,055
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Benefits payable$10,196$9,264
Trade accounts payable and accrued expenses7,6005,238
Book overdraft246298
Unearned revenues7,536286
Short-term debt2,2452,092
Total current liabilities27,82317,178
Long-term debt9,4839,034
Other long-term liabilities1,5951,473
Total liabilities38,90127,685
Stockholders’ equity:
Preferred stock, $1 par; 10,000,000 shares authorized; none issued——
Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,690,082 shares issued at September 30, 2023 and 198,666,598 shares issued at December 31, 20223333
Capital in excess of par value3,3623,246
Retained earnings28,19125,492
Accumulated other comprehensive loss(1,503)(1,304)
Treasury stock, at cost, 75,579,362 shares at September 30, 2023 and 73,691,955 shares at December 31, 2022(13,134)(12,156)
Total stockholders' equity16,94915,311
Noncontrolling interests5559
Total equity17,00415,370
Total liabilities and equity$55,905$43,055

See accompanying notes to condensed consolidated financial statements.

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

Three months ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions, except per share results)
Revenues:
Premiums$25,099$21,468$76,144$66,437
Services1,0161,1592,9933,772
Investment income308172775222
Total revenues26,42322,79979,91270,431
Operating expenses:
Benefits21,74518,38465,61257,108
Operating costs3,2713,0619,3619,120
Depreciation and amortization201182578527
Total operating expenses25,21721,62775,55166,755
Income from operations1,2061,1724,3613,676
Gain on sale of Gentiva Hospice—(240)—(240)
Interest expense114102347293
Other (income) expense, net(6)1340(16)
Income before income taxes and equity in net losses1,0981,2973,9743,639
Provision for income taxes256107911820
Equity in net (losses) earnings(12)3(39)1
Net income$830$1,193$3,024$2,820
Net loss attributable to noncontrolling interests2261
Net income attributable to Humana$832$1,195$3,030$2,821
Basic earnings per common share$6.74$9.45$24.37$22.27
Diluted earnings per common share$6.71$9.39$24.26$22.16

See accompanying notes to condensed consolidated financial statements.

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

Three months ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
Net income attributable to Humana$832$1,195$3,030$2,821
Other comprehensive income (loss):
Change in gross unrealized investment losses(365)(590)(314)(1,982)
Effect of income taxes8513573455
Total change in unrealized investment losses, net of tax(280)(455)(241)(1,527)
Reclassification adjustment for net realized losses3505623
Effect of income taxes—(11)(14)(5)
Total reclassification adjustment, net of tax3394218
Other comprehensive loss, net of tax(277)(416)(199)(1,509)
Comprehensive income attributable to Humana$555$779$2,831$1,312

See accompanying notes to condensed consolidated financial statements.

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

Common StockCapital In Excess of Par ValueRetained EarningsAccumulated Other Comprehensive LossTreasury StockTotal Stockholders' EquityNoncontrolling InterestsTotal Equity
Issued SharesAmount
(dollars in millions, share amounts in thousands)
Three months ended September 30, 2023
Balances, June 30, 2023198,690$33$3,313$27,468$(1,226)$(12,754)$16,834$57$16,891
Net income832832(2)830
Other comprehensive loss(277)(277)(277)
Common stock repurchases—(383)(383)(383)
Dividends and dividend equivalents—(109)(109)(109)
Stock-based compensation535353
Restricted stock unit vesting——(3)3——
Stock option exercises——(1)—(1)(1)
Balances, September 30, 2023198,690$33$3,362$28,191$(1,503)$(13,134)$16,949$55$17,004
Three months ended September 30, 2022
Balances, June 30, 2022198,667$33$3,153$24,511$(1,051)$(11,156)$15,490$20$15,510
Net income1,1951,195(2)1,193
Distribution from noncontrolling interest holders, net33
Sale of Gentiva Hospice(11)(11)
Acquisition5353
Other comprehensive loss(416)(416)(416)
Common stock repurchases—(4)(4)(4)
Dividends and dividend equivalents—(100)(100)(100)
Stock-based compensation808080
Restricted stock unit vesting——(3)3——
Stock option exercises——4599
Balances, September 30, 2022198,667$33$3,234$25,606$(1,467)$(11,152)$16,254$63$16,317

See accompanying notes to condensed consolidated financial statements.

Common StockCapital In Excess of Par ValueRetained EarningsAccumulated Other Comprehensive (Loss) incomeTreasury StockTotal Stockholders' EquityNoncontrolling InterestsTotal Equity
Issued SharesAmount
(dollars in millions, share amounts in thousands)
Nine months ended September 30, 2023
Balances, December 31, 2022198,667$33$3,246$25,492$(1,304)$(12,156)$15,311$59$15,370
Net income3,0303,030(6)3,024
Distribution from noncontrolling interest holders, net—77
Acquisition—(5)(5)
Other comprehensive loss(199)(199)(199)
Common stock repurchases—(1,011)(1,011)(1,011)
Dividends and dividend equivalents—(331)(331)(331)
Stock-based compensation142142142
Restricted stock unit vesting23—(30)30——
Stock option exercises——4377
Balances, September 30, 2023198,690$33$3,362$28,191$(1,503)$(13,134)$16,949$55$17,004
Nine months ended September 30, 2022
Balances, December 31, 2021198,649$33$3,082$23,086$42$(10,163)$16,080$23$16,103
Net income2,8212,821(1)2,820
Distribution to noncontrolling interest holders, net—(1)(1)
Sale of Gentiva Hospice—(11)(11)
Acquisition—5353
Other comprehensive loss(1,509)(1,509)(1,509)
Common stock repurchases—(1,032)(1,032)(1,032)
Dividends and dividend equivalents—(301)(301)(301)
Stock-based compensation173173173
Restricted stock unit vesting18—(31)31——
Stock option exercises——10122222
Balances, September 30, 2022198,667$33$3,234$25,606$(1,467)$(11,152)$16,254$63$16,317

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

For the nine months ended September 30,
20232022
(in millions)
Cash flows from operating activities
Net income$3,024$2,820
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on sale of Gentiva Hospice—(240)
Loss on investment securities, net49136
Equity in net losses (earnings)39(1)
Stock-based compensation142173
Depreciation628555
Amortization5173
Impairment of property and equipment31144
Deferred income taxes—(33)
Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:
Receivables(126)11
Other assets(935)(465)
Benefits payable870948
Other liabilities39(195)
Unearned revenues7,2505,758
Other5330
Net cash provided by operating activities11,1159,714
Cash flows from investing activities
Proceeds from sale of Gentiva Hospice, net—2,708
Acquisitions, net of cash and cash equivalents acquired(223)(293)
Purchases of property and equipment, net(721)(862)
Purchases of investment securities(3,366)(4,740)
Proceeds from maturities of investment securities8851,214
Proceeds from sales of investment securities8151,979
Net cash (used in) provided by investing activities(2,610)6
Cash flows from financing activities
Receipts from contract deposits, net2,4813,787
Proceeds from issuance of senior notes, net1,215744
Repayments of senior notes(1,719)—
Proceeds from issuance (repayments) of commercial paper, net1,618(660)
Repayment of term loan(500)(2,000)
Debt issue costs(4)(2)
Change in book overdraft(52)(89)
Common stock repurchases(1,002)(1,032)
Dividends paid(320)(291)
Other(135)(13)
Net cash provided by financing activities1,582444
Increase in cash and cash equivalents10,08710,164
Cash and cash equivalents at beginning of period5,0613,394
Cash and cash equivalents at end of period$15,148$13,558

Humana Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS—(Continued)

(Unaudited)

For the nine months ended September 30,
20232022
(in millions)
Supplemental cash flow disclosures:
Interest payments$317$256
Income tax payments, net$957$751
Details of businesses acquired in purchase transactions:
Fair value of assets acquired, net of cash and cash equivalents acquired$454$411
Less: Fair value of liabilities assumed(236)(65)
Less: Noncontrolling interests acquired5(53)
Cash paid for acquired businesses, net of cash and cash equivalents acquired$223$293

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. BASIS OF PRESENTATION AND SIGNIFICANT EVENTS

The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2022, that was filed with the Securities and Exchange Commission, or the SEC, on February 16, 2023. We refer to this Form 10-K as the “2022 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.

The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.

Employer Group Commercial Medical Products Business Exit

In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.

Value Creation Initiatives

During 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities beginning in 2023, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, during the three and nine months ended September 30, 2022, we recorded charges of $82 million and $285 million, respectively. For the three and nine months ended September 30, 2022, these charges primarily relate to $4 million and $144 million, respectively, in asset impairments, including software and abandonment, and $44 million and $65 million, respectively, of severance charges in connection with workforce optimization. The remainder of the charges primarily relate to external consulting fees. During the three months ended September 30, 2023, we recorded charges of $52 million primarily in asset impairments relating to software and abandonment. In connection with these initiatives, we expect to incur additional charges through the end of 2024. These charges are recorded at the corporate level and not allocated to the segments.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

COVID-19

The emergence and spread of the novel coronavirus, or COVID-19, beginning in the first quarter of 2020 has impacted our business. Initially during periods of increased incidences of COVID-19, a reduction in non-COVID-19 hospital admissions for non-emergent and elective medical care have resulted in lower overall healthcare system utilization. At the same time, COVID-19 treatment and testing costs increased utilization. During 2022, we experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the Omicron variant outpaced the increase in non-COVID-19 utilization. The significant disruption in utilization during 2020 also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles, and, as such, significantly affected our 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted our claim reserve development and operating cash flows for 2021.

The COVID-19 National Emergency declared in 2020 was terminated on April 10, 2023 and the Public Health Emergency expired on May 11, 2023.

Revenue Recognition

Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

At September 30, 2023, accounts receivable related to services were $322 million. For the three and nine months ended September 30, 2023, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the condensed consolidated balance sheet at September 30, 2023.

For the three and nine months ended September 30, 2023, services revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. Further, services revenue expected to be recognized in any future year related to remaining performance obligations was not material.

2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The new guidance relates to accounting for long-duration contracts of insurers which revises key elements of the measurement models and disclosure requirements for long-duration contracts issued by insurers, including the amortization of deferred contract acquisition costs and the measurement of liabilities for future policy benefits using current, rather than locked-in, assumptions. The new guidance, limited to our Medicare Supplement product which represents less than 1% of consolidated premiums and services revenue, became effective for us beginning January 1, 2023 and is to be applied to contracts in force on the basis of their

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

existing carrying value amounts at the beginning of the earliest period presented. The adoption of the new standard in 2023 did not have a material impact on our consolidated results of operations, financial position or cash flows.

There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.

3. ACQUISITIONS AND DIVESTITURES

On August 11, 2022, we completed the sale of a 60% interest in Gentiva (formerly Kindred) Hospice to Clayton, Dubilier & Rice, or CD&R, for cash proceeds of approximately $2.7 billion, net of cash disposed, including debt repayments from Gentiva Hospice to Humana of $1.9 billion. In connection with the sale we recognized a pre-tax gain, net of transaction costs, of $240 million. For the three and nine months ended September 30, 2022, the accompanying condensed consolidated statement of income includes revenues related to Gentiva Hospice of $177 million and $958 million, respectively, and pretax earnings of $24 million and $150 million, respectively.

During 2023 and 2022, we acquired various health and wellness related businesses which, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses acquired in 2023 and 2022 have been included in our condensed consolidated statements of income and condensed consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in 2023 and 2022 were not material to our results of operations. For asset acquisitions, the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the year of acquisition, were not material for disclosure purposes.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

4. INVESTMENT SECURITIES

Investment securities classified as current and long-term were as follows at September 30, 2023 and December 31, 2022, respectively:

Amortized CostGross Unrealized GainsGross Unrealized LossesFair Value
(in millions)
September 30, 2023
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$2,043$—$(105)$1,938
Mortgage-backed securities3,890—(637)3,253
Tax-exempt municipal securities848—(50)798
Mortgage-backed securities:
Residential497—(85)412
Commercial1,475—(155)1,320
Asset-backed securities1,849—(65)1,784
Corporate debt securities6,86414(868)6,010
Total debt securities$17,466$14$(1,965)15,515
Common stock—
Total investment securities$15,515
December 31, 2022
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$1,093$1$(55)$1,039
Mortgage-backed securities3,6974(471)3,230
Tax-exempt municipal securities765—(37)728
Mortgage-backed securities:
Residential477—(76)401
Commercial1,554—(155)1,399
Asset-backed securities1,8091(79)1,731
Corporate debt securities6,5513(828)5,726
Total debt securities$15,946$9$(1,701)14,254
Common stock7
Total investment securities$14,261

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

We held certain corporate debt securities of Gentiva Hospice at September 30, 2023 with amortized cost and fair value of approximately $281 million and $295 million, respectively.

Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at September 30, 2023 and December 31, 2022, respectively:

Less than 12 months12 months or moreTotal
Fair ValueGross Unrealized LossesFair ValueGross Unrealized LossesFair ValueGross Unrealized Losses
(in millions)
September 30, 2023
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$1,483$(51)$407$(54)$1,890$(105)
Mortgage-backed securities1,084(66)2,169(571)3,253(637)
Tax-exempt municipal securities278(6)515(44)793(50)
Mortgage-backed securities:
Residential48(1)363(84)411(85)
Commercial15—1,304(155)1,319(155)
Asset-backed securities343(6)1,430(59)1,773(65)
Corporate debt securities961(35)4,648(833)5,609(868)
Total debt securities$4,212$(165)$10,836$(1,800)$15,048$(1,965)
December 31, 2022
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$512$(5)$397$(50)$909$(55)
Mortgage-backed securities1,231(104)1,683(367)2,914(471)
Tax-exempt municipal securities64(2)615(36)679(38)
Mortgage-backed securities:
Residential124(16)274(60)398(76)
Commercial243(13)1,157(142)1,400(155)
Asset-backed securities620(32)1,011(46)1,631(78)
Corporate debt securities1,625(98)3,825(730)5,450(828)
Total debt securities$4,419$(270)$8,962$(1,431)$13,381$(1,701)

Approximately 98% of our debt securities were investment-grade quality, with a weighted average credit rating of AA by Standard & Poor's Rating Service, or S&P, at September 30, 2023. Most of the debt securities that were below investment-grade were rated BB-, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding approximately 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.

Our unrealized losses from all debt securities were generated from approximately 1,790 positions out of a total of approximately 2,070 positions at September 30, 2023. All issuers of debt securities we own that were trading at an unrealized loss at September 30, 2023 remain current on all contractual payments. After taking into account these

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time these debt securities were purchased. At September 30, 2023, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position for the three and nine months ended September 30, 2023 or 2022.

The detail of gains (losses) related to investment securities and included within investment income was as follows for the three and nine months ended September 30, 2023 and 2022:

Three months ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)(in millions)
Gross gains on investment securities$—$2$15$41
Gross losses on investment securities(4)(52)(65)(58)
Gross gains on equity securities—51151
Gross losses on equity securities———(170)
Net recognized (losses) gains on investment securities$(4)$1$(49)$(136)

The gains and losses related to equity securities for the three and nine months ended September 30, 2023 and 2022 was as follows:

Three months ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)(in millions)
Net gains (losses) recognized on equity securities during the period$—$51$1$(119)
Less: Net gains (losses) recognized on equity securities sold during the period—47—(105)
Unrealized gains (losses) recognized on equity securities still held at the end of the period$—$4$1$(14)

The contractual maturities of debt securities available for sale at September 30, 2023, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

Amortized CostFair Value
(in millions)
Due within one year$659$654
Due after one year through five years4,8504,565
Due after five years through ten years3,0172,573
Due after ten years1,229954
Mortgage and asset-backed securities7,7116,769
Total debt securities$17,466$15,515

For additional information regarding our investment securities, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

5. FAIR VALUE

Financial Assets

The following table summarizes our fair value measurements at September 30, 2023 and December 31, 2022, respectively, for financial assets measured at fair value on a recurring basis:

Fair Value Measurements Using
Fair ValueQuoted Prices in Active Markets (Level 1)Other Observable Inputs (Level 2)Unobservable Inputs (Level 3)
(in millions)
September 30, 2023
Cash equivalents$15,035$15,035$—$—
Debt securities:
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations1,938—1,938—
Mortgage-backed securities3,253—3,253—
Tax-exempt municipal securities798—798—
Mortgage-backed securities:
Residential412—412—
Commercial1,320—1,320—
Asset-backed securities1,784—1,784—
Corporate debt securities6,010—5,905105
Total debt securities15,515—15,410105
Total invested assets$30,550$15,035$15,410$105
December 31, 2022
Cash equivalents$4,832$4,832$—$—
Debt securities:
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations1,039—1,039—
Mortgage-backed securities3,230—3,230—
Tax-exempt municipal securities728—728—
Mortgage-backed securities:
Residential401—401—
Commercial1,399—1,399—
Asset-backed securities1,731—1,731—
Corporate debt securities5,726—5,625101
Total debt securities14,254—14,153101
Common stock77——
Total invested assets$19,093$4,839$14,153$101

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

Our Level 3 assets had a fair value of $105 million at September 30, 2023, or 0.3% of our total invested assets. During the nine months ended September 30, 2023 and 2022, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:

For the nine months ended September 30, 2023For the nine months ended September 30, 2022
Private Placements
(in millions)
Beginning balance at January 1$101$68
Total gains or losses:
Realized in earnings——
Unrealized in other comprehensive income(1)—
Purchases13(12)
Sales—44
Maturities(4)—
Transfer out(4)
Balance at September 30$105$100

Interest Rate Swaps

During the third quarter of 2023, we entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on our $750 million of 5.875% senior notes and our $750 million of 5.500% senior notes from fixed rates to variable rates to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities. Our swap agreements, which are considered derivative instruments, exchange the fixed interest rate under our 5.875% and 5.500% senior notes for a variable interest rate based on SOFR. Interest rate swaps with notional amounts of $650 million, maturing September 1, 2032, and $250 million, maturing March 15, 2033, were outstanding on our 5.875% and 5.500% senior notes, respectively, at September 30, 2023. These swap agreements were qualified and designated as a fair value hedge. The swap liability, included within other long-term liabilities on our condensed consolidated balance sheet, was not material at September 30, 2023. We include the gain or loss on the swap agreements in interest expense on our condensed consolidated income statement, the same line item as the offsetting loss or gain on the related senior notes. The gain or loss due to hedge ineffectiveness was not material for the three and nine months ended September 30, 2023.

Financial Liabilities

Our debt is recorded at carrying value in our consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $9.5 billion at September 30, 2023 and $10.0 billion at December 31, 2022. The fair value of our senior notes debt was $8.7 billion at September 30, 2023 and $9.4 billion at December 31, 2022. The fair value of our senior notes debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities. Carrying value approximates fair value for our term loans and commercial paper borrowings. The commercial paper borrowings were $2.2 billion at September 30, 2023. The term loans and commercial paper borrowings were $1.1 billion at December 31, 2022.

Put and Call Options Measured at Fair Value

Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation.

The put and call options fair values associated with our Primary Care Organization strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $410 million and $12 million, respectively, at September 30, 2023. The put and call options fair values, derived from the Monte Carlo simulation, were $267 million and $10 million, respectively, at December 31, 2022. The put liability and call asset are included within other long-term liabilities and other long-term assets, respectively, within our condensed consolidated balance sheets.

The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for each reporting period.

September 30, 2023December 31, 2022
Annualized volatility16.6% - 19.6%16.7% - 20.8%
Credit spread0.9% - 1.4%1.3% - 1.5%
Revenue exit multiple1.5x - 2.5x1.5x - 2.5x
Weighted average cost of capital12.0% - 13.0%11.5% - 12.5%
Long term growth rate3.0%3.0%

The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.

Other Assets and Liabilities Measured at Fair Value

Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances. As disclosed in Note 3, we acquired various health and wellness related businesses during 2023. The net assets acquired and resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs. The net tangible assets including receivables and accrued liabilities were recorded at their carrying value which approximated their fair value due to their short term nature. The fair value of goodwill and other intangible assets were internally estimated based primarily on the income approach. The income approach estimates fair value based on the present value of cash flow that the assets could be expected to generate in the future. We developed internal estimates for expected cash flows in the present value calculation using inputs and significant assumptions that include historical revenues and earnings, revenue growth rates, the amount and timing of future cash flows, discount rates, contributory asset charges and future tax rates, among others. The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.

As disclosed in Note 3, we completed the sale of Gentiva Hospice on August 11, 2022. The carrying value of the assets and liabilities of Gentiva Hospice disposed approximates fair value. The amount of goodwill included in the carrying value is based on the relative fair value of the Home Solutions reporting unit included within the CenterWell segment.

Other than the assets and liabilities acquired during 2023, there were no other material assets or liabilities measured at fair value on a recurring or nonrecurring basis during 2023.

For additional information regarding our fair value measurements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

6. MEDICARE PART D

We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with the Centers for Medicare and Medicaid Services, or CMS. The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at September 30, 2023 and December 31, 2022. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

September 30, 2023December 31, 2022
Risk Corridor SettlementCMS Subsidies/ DiscountsRisk Corridor SettlementCMS Subsidies/ Discounts
(in millions)
Other current assets$131$517$240$696
Trade accounts payable and accrued expenses(150)(3,566)(166)(1,236)
Net current (liability) asset(19)(3,049)74(540)
Other long-term assets235—19—
Other long-term liabilities(123)—(78)—
Net long-term asset (liability)112—(59)—
Total net asset (liability)$93$(3,049)$15$(540)

7. GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the carrying amount of goodwill for our reportable segments for the nine months ended September 30, 2023 were as follows:

InsuranceCenterWellTotal
(in millions)
Balance at January 1, 2023$2,472$6,670$9,142
Acquisitions191207398
Balance at September 30, 2023$2,663$6,877$9,540

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at September 30, 2023 and December 31, 2022:

September 30, 2023December 31, 2022
Weighted Average LifeCostAccumulated AmortizationNetCostAccumulated AmortizationNet
($ in millions)
Other intangible assets:
Certificates of needIndefinite$1,132$—$1,132$1,132$—$1,132
Medicare licensesIndefinite302—302286—286
Customer contracts/ relationships9.4 years955708247929673256
Trade names and technology6.7 years1391063314210735
Provider contracts11.6 years73649736310
Noncompetes and other8.4 years844242864046
Total other intangible assets9.2 years$2,685$920$1,765$2,648$883$1,765

For the three months ended September 30, 2023 and 2022, amortization expense for other intangible assets was approximately $17 million and $25 million, respectively. For the nine months ended September 30, 2023 and 2022, amortization expense for other intangible assets was approximately $51 million and $61 million, respectively. The following table presents our estimate of amortization expense remaining for 2023 and each of the next five succeeding years at September 30, 2023:

(in millions)
For the years ending December 31,
2023$15
202460
202558
202644
202734
202829

For additional information regarding our goodwill and intangible assets, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

8. BENEFITS PAYABLE

On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the nine months ended September 30, 2023 and 2022:

For the nine months ended September 30,
20232022
(in millions)
Balances, beginning of period$9,264$8,289
Acquisitions62—
Incurred related to:
Current year66,37057,512
Prior years(758)(404)
Total incurred65,61257,108
Paid related to:
Current year(56,700)(48,835)
Prior years(8,042)(7,325)
Total paid(64,742)(56,160)
Balances, end of period$10,196$9,237

The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net incurred claims amounts. At September 30, 2023, benefits payable included IBNR of approximately $6.4 billion, primarily associated with claims incurred in 2023.

Amounts incurred related to prior periods vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).

Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

9. EARNINGS PER COMMON SHARE COMPUTATION

Detail supporting the computation of basic and diluted earnings per common share was as follows for the three and nine months ended September 30, 2023 and 2022:

Three months ended September 30,Nine Months Ended September 30,
2023202220232022
(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders$832$1,195$3,030$2,821
Weighted average outstanding shares of common stock used to compute basic earnings per common share123,426126,572124,335126,678
Dilutive effect of:
Employee stock options26613150
Restricted stock531723519577
Shares used to compute diluted earnings per common share123,983127,356124,885127,305
Basic earnings per common share$6.74$9.45$24.37$22.27
Diluted earnings per common share$6.71$9.39$24.26$22.16
Number of antidilutive stock options and restricted stock excluded from computation13778251267

For additional information regarding earnings per common share, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

10. STOCKHOLDERS’ EQUITY

Dividends

The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2023 under our Board approved quarterly cash dividend policy:

Record DatePayment DateAmount per ShareTotal Amount
(in millions)
12/30/20221/27/2023$0.7875$98
03/31/202304/28/2023$0.8850$111
06/30/202307/28/2023$0.8850$110
9/29/202310/27/2023$0.8850$109

In October 2023, the Board declared a cash dividend of $0.885 per share payable on January 26, 2024 to stockholders of record as of the close of business on December 29, 2023. Declaration and payment of future quarterly dividends are at the discretion of our Board and may be adjusted as business needs or market conditions change.

Stock Repurchases

Our Board of Directors may authorize the purchase of our common stock shares. Under the share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

amended, or in privately-negotiated transactions, including pursuant to accelerated share repurchase agreements with investment banks, subject to certain regulatory restrictions on volume, pricing, and timing.

On February 15, 2023, the Board of Directors replaced the previous share repurchase authorization of up to $3 billion (of which approximately $1 billion remained unused) with a new authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2026. During the nine months ended September 30, 2023, we repurchased 2.0 million shares in open market transactions for $980 million at an average price of $478.20 under the current share repurchase authorization. During the nine months ended September 30, 2022, we did not repurchase shares in open market transactions.

Our remaining repurchase authorization was $1.9 billion as of October 31, 2023.

In connection with employee stock plans, we acquired 0.06 million common shares for $31 million and 0.07 million common shares for $32 million during the nine months ended September 30, 2023 and 2022, respectively.

For additional information regarding our stockholders' equity, refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

11. INCOME TAXES

The effective income tax rate was 23.5% and 23.1% for the three and nine months ended September 30, 2023, respectively, and 8.2% and 22.5% for the three and nine months ended September 30, 2022, respectively. The year-over-year increase in the effective income tax rate is primarily due to the August 2022 disposition of our 60% interest in Gentiva Hospice, which resulted in an increase to our tax basis in both the shares sold and the shares retained, thereby reducing the effective income tax rate for the three and nine months ended September 30, 2022.

For additional information regarding income taxes, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

12. DEBT

The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at September 30, 2023 and December 31, 2022:

September 30, 2023December 31, 2022
(in millions)
Short-term debt:
Commercial paper$2,245$595
Senior notes:
$1.5 billion, 0.650% due August 3, 2023—1,497
Total senior notes—1,497
Total short-term debt$2,245$2,092
Long-term debt:
Senior notes:
$600 million, 3.850% due October 1, 2024$572$599
$600 million, 4.500% due April 1, 2025598597
$500 million, 5.700% due March 13, 2026497—
$750 million, 1.350% due February 3, 2027688745
$600 million, 3.950% due March 15, 2027537597
$500 million, 5.750% due March 1, 2028495494
$750 million, 3.700% due March 23, 2029689743
$500 million, 3.125% due August 15, 2029458496
$500 million, 4.875% due April 1, 2030496495
$750 million, 2.150% due February 3, 2032743743
$750 million, 5.875% due March 1, 2033715739
$250 million, 8.150% due June 15, 2038261261
$400 million, 4.625% due December 1, 2042396396
$750 million, 4.950% due October 1, 2044740740
$400 million, 4.800% due March 15, 2047396396
$500 million, 3.950% due August 15, 2049493493
$750 million, 5.500% due March 15, 2053709—
Total senior notes9,4838,534
Term loans:
Delayed draw term loan, due May 28, 2024—500
Total term loans—500
Total long-term debt$9,483$9,034

Senior Notes

In March 2023, we issued $500 million of 5.700% unsecured senior notes due March 13, 2026 and $750 million of 5.500% unsecured senior notes due March 15, 2053. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.2 billion. We used the net proceeds to repay outstanding amounts under our $500 million Delayed Draw Term Loan. The remaining net proceeds will be used for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.

In August 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $750 million aggregate principal amount of 1.350% senior notes maturing in February 2027, our $600 million aggregate principal amount of 3.950% senior notes maturing in March 2027, our $750 million aggregate principal amount of 3.700%

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

senior notes maturing in March 2029, and our $500 million aggregate principal amount of 3.125% senior notes maturing in August 2029 during the period beginning on August 7, 2023 and ending on November 15, 2023. For the three months ended September 30, 2023, we repurchased $213 million principal amount of these senior notes for approximately $196 million cash.

In March 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $1.5 billion aggregate principal amount of 0.650% senior notes maturing in August 2023 and our $600 million aggregate principal amount of 3.850% senior notes maturing in October 2024 during the period beginning on March 13, 2023 and ending on July 21, 2023. For the nine months ended September 30, 2023, we repurchased $361 million principal amount of these senior notes for approximately $358 million cash. In August 2023, we repaid the remaining $1.2 billion aggregate principal amount of our 0.650% senior notes due on their maturity date of August 3, 2023.

During the third quarter of 2023, we entered into interest rate swap agreements to exchange the fixed interest rate under our 5.875% and 5.500% senior notes for a variable interest rate based on SOFR, as further described in Note 5. As a result, the carrying value of these senior notes has been adjusted to reflect changes in value caused by an increase or decrease in interest rates. The cumulative, aggregate adjustment to the carrying value of the 5.875% and 5.500% senior notes was $26 million and $5 million, respectively, at September 30, 2023.

For additional information regarding our Senior Notes, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Revolving Credit Agreements

In June 2023, we entered into an amended and restated 5-year, $2.5 billion unsecured revolving credit agreement (replacing the 5-year, $2.5 billion unsecured revolving credit agreement entered in June 2021) and entered into a 364-day $1.5 billion unsecured revolving credit agreement (replacing the 364-day $1.5 billion unsecured revolving credit agreement entered in June 2022, which expired in accordance with its terms).

Under the credit agreements, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option.

The SOFR spread, currently 103.5 basis points under the 5-year revolving credit agreement and 105.5 basis points under the 364-day revolving credit agreement, varies depending on our credit ratings ranging from 92.0 to 130.0 basis points under the 5-year revolving credit agreement and from 94.0 to 135.0 basis points under the 364-day revolving credit agreement. We also pay an annual facility fee regardless of utilization. This facility fee, currently 9.0 basis points, under the 5-year revolving credit agreement and 7.0 basis points under the 364-day revolving agreement, varies depending on our credit ratings ranging from 8.0 to 20.0 basis points under the 5-year revolving credit agreement and from 6.0 to 15.0 basis points under the 364-day revolving credit agreement.

Our credit agreements contain customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 60%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of 41.1% as measured in accordance with the revolving credit agreements as of September 30, 2023.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

At September 30, 2023, we had no borrowings and approximately $18 million of letters of credit outstanding under the revolving credit agreements. Accordingly, as of September 30, 2023, we had $2.482 billion of remaining borrowing capacity under the 5-year revolving credit agreement and $1.5 billion of remaining borrowing capacity under the 364-day revolving credit agreement (which excludes the uncommitted $750 million of incremental loan facilities), none of which would be restricted by our financial covenant compliance requirement.

For additional information regarding our Revolving Credit Agreements, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Commercial Paper

Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the nine months ended September 30, 2023 was $2.3 billion, with $2.2 billion outstanding at September 30, 2023 compared to $0.6 billion outstanding at December 31, 2022. The outstanding commercial paper at September 30, 2023 had a weighted average annual interest rate of 5.58%.

For additional information regarding our Commercial Paper refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.

Other Short-term Borrowings

We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At September 30, 2023 we had no outstanding short-term FHLB borrowings.

13. COMMITMENTS, GUARANTEES AND CONTINGENCIES

Government Contracts

Our Medicare products, which accounted for approximately 83% of our total premiums and services revenue for the nine months ended September 30, 2023, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2023, and all of our product offerings filed with CMS for 2023 have been approved.

CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997, or BBA, and the Benefits Improvement and Protection Act of 2000, or BIPA, generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service, or FFS, program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model.

CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies’ risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans.

In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract’s entire health status-related risk adjusted premium amount for the year under audit. In doing so, CMS recognized “that the documentation standard used in RADV audits to determine a contract’s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).” To correct for this difference, CMS stated that it would apply a “Fee-for-Service Adjuster (FFS Adjuster)” as “an offset to the preliminary recovery amount.” This adjuster would be “calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.” CMS stated that this methodology would apply to audits beginning with PY 2011. Humana relied on CMS’s 2012 guidance in submitting MA bids to CMS. Humana also launched a “Self-Audits” program in 2013 that applied CMS’s 2012 RADV audit methodology and included an estimated FFS Adjuster. Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS.

In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster. CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011. On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule). The Final RADV Rule confirmed CMS’s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS’s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed. However, CMS’s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology. CMS instead stated its general plan to rely on “any statistically valid method . . . that is determined to be well-suited to a particular audit.”

We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (“APA”). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana’s actuarially certified bids through PY 2023 preserved Humana’s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. We expect CMS to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without a FFS Adjuster, to CMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years. The Final RADV Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.

In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows.

On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members. It is critical that MA plans

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.

Our state-based Medicaid business, which accounted for approximately 7% of our total premiums and services revenue for the nine months ended September 30, 2023 primarily consisted of serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states.

At September 30, 2023, our Military business, which accounted for approximately 1% of our total premiums and services revenue for the nine months ended September 30, 2023, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprises 32 states and approximately 6 million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the DoD and is currently scheduled to expire on December 31, 2023, unless further extended.

In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the TRICARE East Region by the Defense Health Agency of the DoD. The contract is expected to go into effect in 2024. Until then the T2017 contract remains in place. Under the terms of the award, our service area covers approximately 4.6 million beneficiaries in a region consisting of 24 states and Washington, D.C. The length of the contract is one base year with eight annual option periods, which, if all options are exercised, would result in a total contract length of nine years.

The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.

Legal Proceedings and Certain Regulatory Matters

As previously disclosed, the Civil Division of the United States Department of Justice provided us with an information request in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We cooperated with the Department of Justice, and we have not heard from the Department of Justice on this matter since 2020.

As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned United States of America ex rel. Steven Scott v. Humana Inc., currently pending in United States District Court, Western District of Kentucky, Louisville division. The complaint alleges certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana’s Basic PDP plan, a prescription drug plan offered by us under Medicare Part D. The action seeks damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator could proceed, following notice from the U.S. Government that it was not intervening at that time. On March 31, 2022, the Court denied the parties' Motions for Summary Judgement. We take seriously our obligations to comply with applicable CMS requirements and actuarial standards of practice, and continue to vigorously defend against these allegations. As of September 30, 2023, we have accrued certain anticipated expenses in connection with this matter.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. There is no assurance that we will prevail in the lawsuit. See “Government Contracts” in this footnote to the unaudited Consolidated Financial Statements of this Form 10-Q for additional information regarding this matter.

Other Lawsuits and Regulatory Matters

Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, utilization management practices, pharmacy benefits, access to care, sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.

We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.

As a government contractor, we may also be subject to false claims litigation, such as qui tam lawsuits brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.

A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.

We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.

The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.

14. SEGMENT INFORMATION

During December 2022, we realigned our businesses into two distinct segments: Insurance and CenterWell. The Insurance segment includes the businesses that were previously included in the Retail and Group and Specialty segments, as well as the Pharmacy Benefit Manager, or PBM, business which was previously included in the Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy dispensing services, primary care, and home services. In addition to the new segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization. Prior period segment financial information has been recast to conform to the 2023 presentation.

Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources.

The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our Military business, primarily our T-2017 East Region contract, as well as the operations of our PBM business.

The CenterWell segment includes our pharmacy, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.

Our CenterWell intersegment revenues primarily relate to the operations of CenterWell Pharmacy (our mail- order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics.

In addition, our CenterWell intersegment revenues include revenues earned by certain owned providers derived from certain value-based arrangements with our health plans. Under these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our members. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

We present our condensed consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $5.7 billion and $5.4 billion for the three months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023 and 2022 these amounts were $14.7 billion and $14.2 billion, respectively. In addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy operations, are included with benefits expense. The amount of this expense was $35 million and $30 million for the three months ended September 30, 2023 and 2022, respectively, and $102 million and $89 million for the nine months ended September 30, 2023 and 2022, respectively.

Other than those described previously, the accounting policies of each segment are the same. For additional information regarding our accounting policies refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home services, to our Insurance segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below.

Our segment results were as follows for the three and nine months ended September 30, 2023 and 2022:

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

InsuranceCenterWellEliminations/ CorporateConsolidated
Three months ended September 30, 2023(in millions)
External revenues
Premiums:
Individual Medicare Advantage$19,637$—$—$19,637
Group Medicare Advantage1,695——1,695
Medicare stand-alone PDP493——493
Total Medicare21,825——21,825
Commercial fully-insured842——842
Specialty benefits252——252
Medicare Supplement185——185
State-based contracts and other1,995——1,995
Total premiums25,099——25,099
Services revenue:
Home solutions—342—342
Primary care—214—214
Commercial ASO55——55
Military and other202——202
Pharmacy solutions—203—203
Total services revenue257759—1,016
Total external revenues25,356759—26,115
Intersegment revenues
Services11,307(1,308)—
Products—2,594(2,594)—
Total intersegment revenues13,901(3,902)—
Investment income154—154308
Total revenues25,5114,660(3,748)26,423
Operating expenses:
Benefits21,976—(231)21,745
Operating costs2,6344,207(3,570)3,271
Depreciation and amortization17953(31)201
Total operating expenses24,7894,260(3,832)25,217
Income from operations722400841,206
Interest expense—1113114
Other income, net——(6)(6)
Income (loss) before income taxes and equity in net earnings722399(23)1,098
Equity in net losses—(12)—(12)
Segment earnings (loss)$722$387$(23)$1,086
Net loss (income) attributable to noncontrolling interests3(1)—2
Segment earnings (loss) attributable to Humana$725$386$(23)$1,088

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

InsuranceCenterWellEliminations/ CorporateConsolidated
Three months ended September 30, 2022(in millions)
External revenues
Premiums:
Individual Medicare Advantage$16,007$—$—$16,007
Group Medicare Advantage1,792——1,792
Medicare stand-alone PDP534——534
Total Medicare18,333——18,333
Commercial fully-insured1,075——1,075
Specialty benefits262——262
Medicare Supplement188——188
State-based contracts and other1,610——1,610
Total premiums21,468——21,468
Services revenue:
Home solutions—519—519
Primary care—159—159
Commercial ASO73——73
Military and other137——137
Pharmacy solutions—271—271
Total services revenue210949—1,159
Total external revenues21,678949—22,627
Intersegment revenues
Services14863(877)—
Products—2,459(2,459)—
Total intersegment revenues143,322(3,336)—
Investment income513118172
Total revenues21,7434,274(3,218)22,799
Operating expenses:
Benefits18,413—(29)18,384
Operating costs2,2943,929(3,162)3,061
Depreciation and amortization16345(26)182
Total operating expenses20,8703,974(3,217)21,627
Income (loss) from operations873300(1)1,172
Gain on sale of Gentiva Hospice—(240)—(240)
Interest expense——102102
Other expense, net——1313
Income (loss) before income taxes and equity in net earnings873540(116)1,297
Equity in net earnings (losses)8(5)—3
Segment earnings (loss)$881$535$(116)$1,300
Net loss attributable to noncontrolling interests2——2
Segment earnings (loss) attributable to Humana$883$535$(116)$1,302

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

InsuranceCenterWellEliminations/ CorporateConsolidated
Nine months ended September 30, 2023(in millions)
External revenues
Premiums:
Individual Medicare Advantage$59,195$—$—$59,195
Group Medicare Advantage5,192——5,192
Medicare stand-alone PDP1,677——1,677
Total Medicare66,064——66,064
Commercial fully-insured2,810——2,810
Specialty benefits758——758
Medicare Supplement546——546
State-based contracts and other5,966——5,966
Total premiums76,144——76,144
Services revenue:
Home solutions—997—997
Primary care—605—605
Commercial ASO190——190
Military and other540——540
Pharmacy solutions—661—661
Total services revenue7302,263—2,993
Total external revenues76,8742,263—79,137
Intersegment revenues
Services303,584(3,614)—
Products—7,848(7,848)—
Total intersegment revenues3011,432(11,462)—
Investment income385—390775
Total revenues77,28913,695(11,072)79,912
Operating expenses:
Benefits66,096—(484)65,612
Operating costs7,59712,526(10,762)9,361
Depreciation and amortization516152(90)578
Total operating expenses74,20912,678(11,336)75,551
Income from operations3,0801,0172644,361
Interest expense—2345347
Other expense, net——4040
Income (loss) before income taxes and equity in net losses3,0801,015(121)3,974
Equity in net losses(2)(37)—(39)
Segment earnings (loss)$3,078$978$(121)$3,935
Net loss (income) attributable to noncontrolling interests7(1)—6
Segment earnings (loss) attributable to Humana$3,085$977$(121)$3,941

Table of Contents

Humana Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(Unaudited)

InsuranceCenterWellEliminations/ CorporateConsolidated
Nine months ended September 30, 2022(in millions)
External Revenues
Premiums:
Individual Medicare Advantage$49,751$—$—$49,751
Group Medicare Advantage5,524——5,524
Medicare stand-alone PDP1,779——1,779
Total Medicare57,054——57,054
Commercial fully-insured3,324——3,324
Specialty benefits784——784
Medicare Supplement555——555
State-based contracts and other4,720——4,720
Total premiums66,437——66,437
Services revenue:
Home solutions—1,997—1,997
Primary care—409—409
Commercial ASO225——225
Military and other395——395
Pharmacy solutions—746—746
Total services revenue6203,152—3,772
Total external revenues67,0573,152—70,209
Intersegment revenues
Services422,614(2,656)—
Products—7,394(7,394)—
Total intersegment revenues4210,008(10,050)—
Investment income143673222
Total revenues67,24213,166(9,977)70,431
Operating expenses:
Benefits57,311—(203)57,108
Operating costs6,48612,002(9,368)9,120
Depreciation and amortization469136(78)527
Total operating expenses64,26612,138(9,649)66,755
Income (loss) from operations2,9761,028(328)3,676
Gain on sale of Gentiva Hospice—(240)—(240)
Interest expense——293293
Other income, net——(16)(16)
Income (loss) before income taxes and equity in net losses2,9761,268(605)3,639
Equity in net earnings (losses)16(15)—1
Segment earnings (loss)$2,992$1,253$(605)$3,640
Net loss (income) attributable to noncontrolling interests2(1)—1
Segment earnings (loss) attributable to Humana$2,994$1,252$(605)$3,641

Table of Contents

Humana Inc.

Next: Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF